Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Topiramate is an anticonvulsant drug used in the control of epilepsy and in the prophylaxis and treatment of migraines. It was initially approved by the FDA in 1996.
- Mechanism
- Curator reviewed · 15 references
A seizure is an abnormal and unregulated electrical discharge occurring in the brain. This leads to transient interruption in brain function, manifested by reduced alertness, abnormal sensations, and focal involuntary movements or convulsions. Several types of seizures exist, with common types including tonic-clonic seizures and partial onset seizures.
The exact mechanisms by which topiramate exerts pharmacological actions on seizures and migraines are currently not fully characterized. Several properties of this drug, however, are likely to contribute to its therapeutic effects. Topiramate has been observed to exert actions on voltage-dependent sodium channels, GABA receptors, and glutamate receptors.
Topiramate stimulates GABA-A receptor activity at brain non-benzodiazepine receptor sites and reduces glutamate activity at both AMPA and kainate receptors. Normally, GABA-A receptors are inhibitory and glutaminergic receptors are stimulatory for neuronal activity. By increasing GABA activity and inhibiting glutamate activity, topiramate blocks neuronal excitability, preventing seizures and migraines. Additionally, it blocks the voltage-dependent sodium channels, further blocking seizure activity. Topiramate has been shown to inhibit various carbonic anhydrase isozymes, but the clinical significance of this is unknown at this time.
- Primary indication
- Topiramate is indicated for the following conditions: 1)Monotherapy for partial onset or primary generalized tonic-clonic seizures for patients 2 years of age and above 2)Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures...Curator reviewed · 17 structured indications
- Formula / weight
- C12H21NO8S · 339.362 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1997
- Code names
- MCN-4853 · RWJ-17021 · RWJ-17021-000 · USL-255
- Brand names
- Eprontia
- Qsymia
- Qudexy
- Topamax
- Trokendi
Resolves to
KJADKKWYZYXHBB-XBWDGYHZSA-NSMILES[H][C@@]12CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@@]3([H])[C@]1([H])OC(C)(C)O2What you can answer from here — as of September 23, 2026
Which drugs share a target with Topiramate, and which of those have an active Phase 3 trial?